FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...
Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsJay Short - Co-Founder, CEO & ChairmanSheri Lydick - ...
A prostate cancer diagnosis and life during and after treatments can feel overwhelming. Alongside the shock of a diagnosis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback